Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZZSW-01 in Relapsed/Refractory B-cell Malignancies
NCT07240974Phase 1Recruiting
- Start
- Oct 2025
- Primary completion
- Sep 2028
- Modality
- Lipid-based Nanoparticles, Cell Therapies, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZZSW-01 in B cell malignancies. Primary endpoints: Incidence of Adverse Events, Incidence of Dose-Limiting Toxicities and 2 more. Started Oct 2025; status: recruiting.
02
Drugs
ZZSW-01
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT07240974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240974.